Page 56 - Read Online

Page 50 Loong et al. J Transl Genet Genom 2023;7:27-49 https://dx.doi.org/10.20517/jtgg.2022.20

rarely de novo. Circ Genom Precis Med 2019;12:e002467. DOI PubMed
48. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and
management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019;16:e301-72. DOI
49. James CA, Syrris P, van Tintelen JP, Calkins H. The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. Eur
Heart J 2020;41:1393-400. DOI PubMed
50. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/
cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:847-55. DOI PubMed
51. Engberding R, Bender F. [Echocardiographic detection of persistent myocardial sinusoids]. Z Kardiol 1984;73:786-8. PubMed
52. Murphy RT, Thaman R, Blanes JG, et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur
Heart J 2005;26:187-92. DOI PubMed
53. Ross SB, Jones K, Blanch B, et al. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in
adults. Eur Heart J 2020;41:1428-36. DOI PubMed
54. Bennett CE, Freudenberger R. The current approach to diagnosis and management of left ventricular noncompaction
cardiomyopathy: review of the literature. Cardiol Res Pract 2016;2016:5172308. DOI PubMed PMC
55. Ichida F, Hamamichi Y, Miyawaki T, et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term
clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol 1999;34:233-40. DOI PubMed
56. Sedaghat-Hamedani F, Haas J, Zhu F, et al. Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. Eur
Heart J 2017;38:3449-60. DOI PubMed
57. Ichida F, Tsubata S, Bowles KR, et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome.
Circulation 2001;103:1256-63. DOI PubMed
58. Probst S, Oechslin E, Schuler P, et al. Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not
predict clinical phenotype. Circ Cardiovasc Genet 2011;4:367-74. DOI
59. Hastings R, de Villiers CP, Hooper C, et al. Combination of whole genome sequencing, linkage, and functional studies implicates a
missense mutation in titin as a cause of autosomal dominant cardiomyopathy with features of left ventricular noncompaction. Circ
Cardiovasc Genet 2016;9:426-35. DOI
60. Wang C, Hata Y, Hirono K, et al. A wide and specific spectrum of genetic variants and genotype-phenotype correlations revealed by
next-generation sequencing in patients with left ventricular noncompaction. J Am Heart Assoc 2017:6. DOI PubMed PMC
61. Li S, Zhang C, Liu N, et al. Genotype-positive status is associated with poor prognoses in patients with left ventricular
noncompaction cardiomyopathy. J Am Heart Assoc 2018;7:e009910. DOI PubMed PMC
62. Stöllberger C, Blazek G, Dobias C, Hanafin A, Wegner C, Finsterer J. Frequency of stroke and embolism in left ventricular
hypertrabeculation/noncompaction. Am J Cardiol 2011;108:1021-3. DOI PubMed
63. Caliskan K, Szili-Torok T, Theuns DA, et al. Indications and outcome of implantable cardioverter-defibrillators for primary and
secondary prophylaxis in patients with noncompaction cardiomyopathy. J Cardiovasc Electrophysiol 2011;22:898-904. DOI
PubMed
64. Sekijima Y. Hereditary transthyretin amyloidosis. In: Adam MP, Everman DB, Mirzaa GM, et al, editors. Seattle: University of
Washington, 1993.
65. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac
amyloidosis. Circ Heart Fail 2019;12:e006075. DOI PubMed PMC
66. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement
from the american heart association. Circulation 2020;142:e7-e22. DOI
67. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl
J Med 2018;379:1007-16. DOI
68. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013;47:157-62. DOI PubMed
69. Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the
Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J 2019;43:391-400. DOI PubMed PMC
70. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and
electrocardiographic syndrome. a multicenter report. J Am Coll Cardiol 1992;20:1391-6. DOI PubMed
71. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present status of brugada syndrome: JACC state-of-the-art
review. J Am Coll Cardiol 2018;72:1046-59. DOI PubMed
72. Sieira J, Brugada P. The definition of the brugada syndrome. Eur Heart J 2017;38:3029-34. DOI PubMed
73. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature
1998;392:293-6. DOI PubMed
74. Monasky MM, Micaglio E, Locati ET, Pappone C. Evaluating the use of genetics in brugada syndrome risk stratification. Front
Cardiovasc Med 2021;8:652027. DOI PubMed PMC
75. Rehm HL, Berg JS, Brooks LD, et al. ClinGen-the clinical genome resource. N Engl J Med 2015;372:2235-42. DOI PubMed PMC
76. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter
ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011;123:1270-9. DOI PubMed
77. Lieve KV, Wilde AA. Inherited ion channel diseases: a brief review. Europace 2015;17 Suppl 2:ii1-6. DOI PubMed
78. Watanabe H, Minamino T. Genetics of Brugada syndrome. J Hum Genet 2016;61:57-60. DOI PubMed